Angiotech Pharmaceuticals
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1992  |
| Headquarters | , |
Key people | K. Thomas Bailey |
Number of employees | 1450[1] |
| Website | www.angiotech.com |
Angiotech was a pharmaceutical company in Vancouver, British Columbia, Canada. Angiotech was founded in 1992 by William L. Hunter, Lindsay Machan, and Larry Arsenault. It sought to develop innovative technologies and medical products primarily for local diseases and complications associated with medical device implants, surgical interventions and acute injury.
In April 2010, Angiotech acquired Haemacure manufacturing to develop human biological adhesives, hemostats and therapeutic proteins.[citation needed]
In 2017, Angiotech was acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital.[2]
References[edit]
- ^ "Company Profile for Angiotech Pharmaceuticals Inc (CA;ANP)". Archived from the original on 2012-02-29. Retrieved 2008-10-10.
- ^ Falconer, Kirk (2016-12-19). "Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group". PE Hub. Retrieved 2019-10-28.
External links[edit]
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 | This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it. |